GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laboratorio Reig Jofre SA (XMAD:RJF) » Definitions » Cyclically Adjusted PS Ratio

Laboratorio Reig Jofre (XMAD:RJF) Cyclically Adjusted PS Ratio : 0.78 (As of May. 15, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Laboratorio Reig Jofre Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Laboratorio Reig Jofre's current share price is €2.82. Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €3.63. Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio for today is 0.78.

The historical rank and industry rank for Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio or its related term are showing as below:

XMAD:RJF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.6   Med: 0.79   Max: 2.07
Current: 0.78

During the past years, Laboratorio Reig Jofre's highest Cyclically Adjusted PS Ratio was 2.07. The lowest was 0.60. And the median was 0.79.

XMAD:RJF's Cyclically Adjusted PS Ratio is ranked better than
77.99% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs XMAD:RJF: 0.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Laboratorio Reig Jofre's adjusted revenue per share data for the three months ended in Dec. 2023 was €1.000. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.63 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Laboratorio Reig Jofre Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Reig Jofre Cyclically Adjusted PS Ratio Chart

Laboratorio Reig Jofre Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 1.48 1.03 0.63 0.62

Laboratorio Reig Jofre Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.63 - 0.68 0.62

Competitive Comparison of Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio falls into.



Laboratorio Reig Jofre Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.82/3.63
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Laboratorio Reig Jofre's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1/121.2698*121.2698
=1.000

Current CPI (Dec. 2023) = 121.2698.

Laboratorio Reig Jofre Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.413 100.597 0.498
201312 0.369 101.306 0.442
201403 2.483 100.139 3.007
201406 -1.404 101.081 -1.684
201409 5.817 100.441 7.023
201412 -1.271 100.251 -1.537
201503 0.683 99.474 0.833
201506 0.606 101.138 0.727
201509 0.594 99.559 0.724
201512 0.647 100.268 0.783
201603 0.673 98.638 0.827
201606 0.651 100.333 0.787
201609 0.569 99.737 0.692
201612 0.666 101.842 0.793
201703 0.696 100.896 0.837
201706 0.642 101.848 0.764
201709 0.553 101.524 0.661
201712 0.758 102.975 0.893
201803 0.729 102.122 0.866
201806 0.683 104.165 0.795
201809 0.667 103.818 0.779
201812 0.728 104.193 0.847
201903 0.764 103.488 0.895
201906 0.575 104.612 0.667
201909 0.718 103.905 0.838
201912 0.702 105.015 0.811
202003 0.820 103.469 0.961
202006 0.711 104.254 0.827
202009 0.723 103.521 0.847
202012 0.783 104.456 0.909
202103 0.815 104.857 0.943
202106 0.708 107.102 0.802
202109 0.743 107.669 0.837
202112 0.822 111.298 0.896
202206 0.000 118.044 0.000
202209 0.808 117.221 0.836
202212 0.978 117.650 1.008
202306 0.000 120.278 0.000
202309 1.032 121.343 1.031
202312 1.000 121.270 1.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Laboratorio Reig Jofre  (XMAD:RJF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Laboratorio Reig Jofre Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorio Reig Jofre (XMAD:RJF) Business Description

Traded in Other Exchanges
Address
Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.